ABO Hemolytic Disease of Newborn

1

Review clinical trials related to ABO Hemolytic Disease of Newborn. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN

A prospective observational cohort study was designed. 1. Comparing of the clinical indicators between the hemolytic group and the non-hemolytic group,such as End-tidal carbon monoxide corrected for ambient CO(ETCOc),direct antiglobulin test(DAT), the highest total serum bilirubin level and hemoglobin. To explore the role of ETCOc in the diagnosis of neonatal ABO hemolytic disease. 2. Comparing of the clinical indicators between the neonates with IVIG treatment and the neonates without IVIG treatment in ABO hemolytic disease, such as ETCOc,total serum bilirubin level before IVIG treatment and ETCOc,total serum bilirubin level after IVIG treatment.To explore the clinical value of ETCOc in the treatment of ABO hemolytic disease.

Participants needed: 112
Trial details
Age: Up to 7Biological sex: AllType: ObservationalSponsor: Women's Hospital School Of Medicine Zhejiang UniversityUpdated: Feb 5, 2025Locations: 1
Eligibility criteria

gestational age between 35+0 and 41+6 weeks [+5]

persistent dyspnea or need for respiratory support [+3]